Patients who received IL-6RAs were younger (median age 57.5 years vs. 61.1 and 61.8 years in the steroid and combination groups, respectively; p = 0.009), and chronic pulmonary diseases, excluding asthma (COPD, bronchiectasis, and interstitial lung disease) were more prevalent in combination group (16 [15.8%] vs. 7 [4.12%] and 59 [10%] in IL-6RA and steroid groups, respectively; p = 0.005). Here, IL6R is linked to interstitial lung disease.